A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...

Semaglutide, the blockbuster drug better known by brand names like Ozempic and Wegovy, has now shown significant promise in ...

A new study reveals that semaglutide, a common diabetes medication, may effectively treat fatty liver disease, offering hope ...

The international study led by a Virginia Commonwealth University researcher found the medication semaglutide, commonly known ...

Key outcomes of all-cause mortality and portal hypertension complications are improved with SGLT2inhibitors, new research ...

Results showed that 62.9% of patients on Ozempic saw a reduction in liver inflammation, compared to 34.3% on placebo.

Semaglutide, a GLP-1 receptor agonist sold under brand names Wegovy and Ozempic, is approved for weight loss and blood sugar ...

How a commonly “silent disease” is driving urgency and novelty in the liver disease treatment paradigm and what can we hope for.

Too Much Chicken? New Research Finds Link to Increased Risk of Early DeathA recent study published in the journal Nutrients ...

Zurich (Switzerland), May 5, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today ...

Financing follows completion of enrollment of Phase 3 NATiV3 study evaluating lanifibranor in MASH and satisfaction of other specified conditions. Daix (France), New York City (New York, United States ...